What is the CVR number of ANTIANTHRA ApS?

ANTIANTHRA ApS is registered with CVR / Virk under CVR 25519108.

What is the revenue of ANTIANTHRA ApS?

ANTIANTHRA ApS reported revenue of DKK -15K in 2013.

Who is the CEO of ANTIANTHRA ApS?

Anders Cold is Unofficial title of ANTIANTHRA ApS, in role since 2011.

Who is the chairman of ANTIANTHRA ApS?

Neil Goldsmith chairs the board of ANTIANTHRA ApS, in role since 2000.

Where is ANTIANTHRA ApS headquartered?

ANTIANTHRA ApS's registered address is Skovbakken 54.

ANTIANTHRA ApS

APSDissolved

CVR 25519108Skovbakken 54Forskning og eksperimentel udvikling indenfor bioteknologi · NACE 721100Est. 2000— employees

Full Risika report

Revenue 2013

DKK -15K

-253% vs 2012

EBITDA margin

100.0%

-253% vs 2012

Equity ratio

94.0%

Financial strength

Net profit 2013

DKK 127K

+19% vs 2012

EBITDA — year on yearDKK millions

Key figuresAnnual report 2013

Revenue	DKK -15K	-253%
EBITDA	DKK -15K	-253%
Net profit	DKK 127K	+19%
Total assets	DKK 280K	-77%
Equity	DKK 263K	-78%
Employees	—	—

Item	2012	2013
Revenue	10	-15
Staff expenses	-0	-0
EBITDA	10	-15
Depreciation & amort.	-0	-0
EBIT	10	-15
Net financials	22	17
Profit before tax	32	2
Tax	-75	-125
Net profit	107	127

Item	2012	2013
Total assets	1.199	280
Equity	1.186	263
Long-term debt	0	0
Short-term debt	13	17
Total debt	13	17

Name	Role	Member since	Age	Other directorships
AC Anders Cold Unofficial title	Unofficial title	2011	—	—
PB PROSPERO BIOTECH LTD Founder	Founder	2000	—	—
PB Peter Buhl Management	Management	2012	—	—

Name	Role	Member since	Age	Other directorships
NG Neil Goldsmith	Board of Directors	2000	—	—
SW Seppo Wang Langer	Board of Directors	2000	—	—
MS Maxwell Sehested	Board of Directors	2000	—	—

Person	Role here	Other companies
Anders Cold	Unofficial title	0 companies
PROSPERO BIOTECH LTD	Founder	0 companies
Peter Buhl	Management	0 companies
Neil Goldsmith	Board of Directors	0 companies
Seppo Wang Langer	Board of Directors	0 companies
Maxwell Sehested	Board of Directors	0 companies

ANTIANTHRA ApS

APSDissolved

CVR 25519108Skovbakken 54Forskning og eksperimentel udvikling indenfor bioteknologi · NACE 721100Est. 2000— employees

Full Risika report

Revenue 2013

DKK -15K

-253% vs 2012

EBITDA margin

100.0%

-253% vs 2012

Equity ratio

94.0%

Financial strength

Net profit 2013

DKK 127K

+19% vs 2012

EBITDA — year on yearDKK millions

Key figuresAnnual report 2013

Revenue	DKK -15K	-253%
EBITDA	DKK -15K	-253%
Net profit	DKK 127K	+19%
Total assets	DKK 280K	-77%
Equity	DKK 263K	-78%
Employees	—	—